NSTG NanoString Technologies

Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced the launch of the Spatial Atlas of Human Anatomy (SAHA) initiative, in collaboration with Weill Cornell Medicine, to create multicellular, single-cell, and sub-cellular maps of 30 non-diseased organs from a healthy and diverse population of adults.

SAHA is a foundational effort to map 250 million cells at two spatial scales: whole transcriptome of histological features (50 µm to 2 mm in length) and 1,000 RNAs and 64 proteins at single cell resolution (50 nm resolution across 1 cm2). The project will establish best practices in experimental design, data analysis, and data standards for high-content spatial analysis across multiple human organs at a whole transcriptome and proteome level. The goal is to create a comprehensive open source, spatial reference standard that can be accessed by researchers around the globe to advance our knowledge of spatial biology.

“The goal is for SAHA to be a foundational database that can serve as a benchmark reference for spatial precision medicine. Comparing spatial datasets of various organs from multiple ethnicities can capture the variability in samples that researchers do not currently understand,” stated Chris Mason, Professor of Physiology and Biophysics, Weill Cornell Medicine. “The research team plans to show how spatial organ atlasing at multiple scales can be used for uncovering unique insights into organ development, health, and cancer.”

Dr. Mason will be presenting an overview of the SAHA study on Monday, February 6th at 6:10pm ET, at the Advances in Genome Biology and Technology conference in Hollywood, FL.

The GeoMx® Digital Spatial Profiler (DSP) will measure the expression of whole transcriptomes matched to the exact shape of functional and structural histological organ features. In addition, the 1,000-plex RNA profiles and 64-plex protein profiles collected by the CosMx™ Spatial Molecular Imager (SMI) will enable the highest-ever subcellular resolution single-cell maps of cell types, lineage states, metabolic capacity, cellular neighborhoods, subcellular movements of organelles, while also detailing spatially resolved and novel ligand-receptor interactions.

“The SAHA data set, obtained at multiple spatial scales, analyte classes, and plex-levels, represents the largest data set of its kind ever collected,” said Joseph Beechem, SVP & CSO of NanoString. “This atlas will transform our understanding of how healthy tissues are organized and function and provide the foundation of understanding required to both treat and diagnose disease states.”

Variability is an important aspect of biological research. The samples, selected to advance medical research, will capture variability across sexes and ancestries (European, African, Latin American, East Asian, and South Asian). All results will be made available to the scientific community through the SAHA data portal, including raw and processed data.

SAHA is a collaborative effort with Weill Cornell Medicine’s Department of Pathology and Laboratory Medicine, Englander Institute for Precision Medicine, and the WorldQuant Initiative for Quantitative Prediction. It will be led by Drs. Chris Mason, Robert E. Schwartz, and Shauna L. Houlihan, and executed in two phases over the next three years. The research will investigate how NanoString’s spatial platforms can synergize for unprecedented biological insights.

Dr. Mason serves on the Scientific Advisory Board and is a paid consultant to NanoString

About NanoString Technologies, Inc.

NanoString Technologies, a leader in , offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler, cited in more than 190 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx™ Spatial Molecular Imager (SMI) is an FFPE-compatible, platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform (SIP) is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. The foundation of our research tools is our nCounter® Analysis System, cited in more than 6,500 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.

For more information, visit .

EN
02/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NanoString Technologies

 PRESS RELEASE

NanoString Reports Inducement Grants Under Nasdaq Listing Rules

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on December 6, 2023, the Compensation and Human Capital Committee of NanoString’s Board of Directors approved the grant of, in the aggregate, 34,925 restricted stock units, or RSUs, as material inducements to the 10 employees entering into employment with NanoString. One-third of the R...

 PRESS RELEASE

NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Health...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, January 10, at 5:15pm ET. Interested parties can access the live webcast from the investor section of the company’s website at . The webcast replay will be available one hour after the conc...

 PRESS RELEASE

NanoString Comments on Delaware District Court Verdict

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty. “We respectfully disagree with the jury’s verdict, which we will seek to have overturned or amend...

 PRESS RELEASE

NanoString to Webcast Presentations from Upcoming Healthcare Conferenc...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. Stifel 2023 Healthcare Conference Tuesday, November 14th Tom Bailey, NanoString’s chief financial officer, and Doug Farrell, VP of Investor Relations, will participate in a fireside discussion hosted by Stifel analyst Dan Arias at 9:45am ET. Jefferies London Healthcare Conference Thursday, November 16th Tom Bailey, Nano...

 PRESS RELEASE

NanoString Technologies Releases Operating Results for Third Quarter o...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. “The last few months have been extraordinarily productive for our team. During the third quarter, we delivered record revenue whi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch